Skip to content
buyNotable cluster of 5

Noubar Afeyan bought $75M of GENB

director, owner at Generate Biomedicines, Inc.. 4,687,500 shares at an average of $16.00, traded Mar 2, 2026, filed Mar 2, 2026.

Conviction score
71
Value
$75M
4,687,500 shares
Holdings after
1,562,500
+34% from before
From 52-week low
0%
low $12.17, close $12.17
From 52-week high
-4%
high $12.65, as of Mar 2, 2026

Score components

  • Role
    Director
    +15
  • Trade size
    $75.0M at market
    +25
  • Relative to holdings
    Holdings up 34%
    +6
  • Price context
    0% above the 52-week low
    +10
  • Cluster
    5 insiders buying within 14 days
    +15
  • Repeat buying
    First buy in 90 days
    0
  • Track record
    Too few past buys to judge (0 with prices)
    0

What happened after comparable buys

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

This signal so far: 1m +9.4%, 3m +6.6%, 6m +25.5%.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

GENBOct 12, 2026 · close 13.84
Since filing Mar 2, 2026: +13.7%SPY +14.2% · excess -0.5%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0001193125-26-085855, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Mar 2, 2026CConversion
Common Stockindirect: By Flagship Pioneering Fund VI, L.P.
+12,723,940--12,723,940Mar 2, 2026
Mar 2, 2026CConversion
Common Stockindirect: By Flagship Pioneering Fund VII, L.P.
+13,702,224--13,702,224Mar 2, 2026
Mar 2, 2026CConversion
Common Stockindirect: By Nutritional Health LTP Fund, L.P.
+987,491--987,491Mar 2, 2026
Mar 2, 2026CConversion
Common Stockindirect: By Flagship Pioneering Special Opportunities Fund II, L.P.
+2,777,752--2,777,752Mar 2, 2026
Mar 2, 2026CConversion
Common Stockindirect: By FPN II, L.P.
+2,777,752--2,777,752Mar 2, 2026
Mar 2, 2026POpen-market purchase
Common Stockindirect: By Flagship Pioneering Fund VII, L.P.
+1,562,500$16.00$25M15,264,724Mar 2, 2026
Mar 2, 2026POpen-market purchase
Common Stockindirect: By FPN II, L.P.
+1,562,500$16.00$25M4,340,252Mar 2, 2026
Mar 2, 2026POpen-market purchase
Common Stockindirect: By Pioneering Medicines 02, LLC
+1,562,500$16.00$25M1,562,500Mar 2, 2026
Feb 26, 2026AGrant or award
Stock Option (Right to Buy)derivative
+29,561$0.00$029,561Mar 2, 2026
Mar 2, 2026CConversion
Series A Preferred Stockderivativeindirect: By Flagship Pioneering Fund VI, L.P.
-18,483,785$0.00$00Mar 2, 2026
Mar 2, 2026CConversion
Series A Preferred Stockderivativeindirect: By Flagship Pioneering Fund VII, L.P.
-17,016,215$0.00$00Mar 2, 2026
Mar 2, 2026CConversion
Series A Preferred Stockderivativeindirect: By Nutritional Health LTP Fund, L.P.
-1,500,000$0.00$00Mar 2, 2026
Mar 2, 2026CConversion
Series B Preferred Stockderivativeindirect: By Flagship Pioneering Fund VI, L.P.
-843,881$0.00$00Mar 2, 2026
Mar 2, 2026CConversion
Series B Preferred Stockderivativeindirect: By Flagship Pioneering Fund VII, L.P.
-1,265,822$0.00$00Mar 2, 2026
Mar 2, 2026CConversion
Series B Preferred Stockderivativeindirect: By Flagship Pioneering Special Opportunities Fund II, L.P.
-2,953,586$0.00$00Mar 2, 2026
Mar 2, 2026CConversion
Series B Preferred Stockderivativeindirect: By FPN II, L.P.
-2,109,704$0.00$00Mar 2, 2026
Mar 2, 2026CConversion
Series C Preferred Stockderivativeindirect: By Flagship Pioneering Fund VII, L.P.
-2,531,644$0.00$00Mar 2, 2026
Mar 2, 2026CConversion
Series C Preferred Stockderivativeindirect: By Flagship Pioneering Special Opportunities Fund II, L.P.
-1,265,822$0.00$00Mar 2, 2026
Mar 2, 2026CConversion
Series C Preferred Stockderivativeindirect: By FPN II, L.P.
-2,109,704$0.00$00Mar 2, 2026

Related signals

Other insiders at Generate Biomedicines, Inc. and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
0Weak
GENBsell10b5-1
Generate Biomedicines, Inc.
Frances Arnold
director
$16k
1,000 shares
-0%
63Notable
GENBbuy 5
Generate Biomedicines, Inc.
Michael Nally
Chief Executive Officer
$240k
20,000 shares
+4%
71Notable
GENBbuy 5
Generate Biomedicines, Inc.
Noubar Afeyan
director, owner
$75M
4,687,500 shares
+34%
48Moderate
GENBbuy 5
Generate Biomedicines, Inc.
Jane L Mendillo
director
$24k
1,500 shares
-
60Notable
GENBbuy 5
Generate Biomedicines, Inc.
Jason Silvers
President & CFO
$32k
2,000 shares
-
48Moderate
GENBbuy 5
Generate Biomedicines, Inc.
Beth Grous
Chief People Officer
$4,800
300 shares
-

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Noubar Afeyan bought $75M of GENB | InsiderTell